Drugs of Today : Impact Factor & More
eISSN: 1699-4019pISSN: 1699-3993
Share this on:
Key Metrics
CiteScore 
3.3
Impact Factor
< 5
SNIP
0.66
Recommended pre-submission checks
Powered by 
Run standard language and technical checks to improve your manuscript – before you submit
Technical Compliance
Ensure manuscript complies with standard submission guidelines.
Language Quality
Improve clarity, grammar, and academic writing style.
A comprehensive report covering all these checks awaits you.
Topics Covered on Drugs of Today
Drugs of Today Journal Specifications
Indexed in the following public directories
Scopus
| Overview | |
| Publisher | PROUS SCIENCE, SAU-THOMSON REUTERS |
| Language | English |
| Frequency | Monthly |
| General Details | |
| Language | English |
| Frequency | Monthly |
| Publication Start Year | 1964 |
| Publisher URL | Visit website |
| Website URL | Visit website |
View less
Planning to publish in Drugs of Today ?
Upload your Manuscript to get
- Degree of match
- Common matching concepts
- Additional journal recommendations
Recently Published Papers in Drugs of Today
New product intros
- 1 Mar 2023
- Drugs of Today
Secukinumab, ixekizumab, bimekizumab and brodalumab for psoriasis and psoriatic arthritis.
- 1 Mar 2023
- Drugs of Today
Tebentafusp: a novel drug for the treatment of metastatic uveal melanoma.
- 1 Mar 2023
- Drugs of Today
Cenegermin for the treatment of dry eye disease.
- 1 Mar 2023
- Drugs of Today
Sugemalimab, a novel PD-L1 inhibitor for treatment of advanced or metastatic non-small cell lung cancer.
- 1 Mar 2023
- Drugs of Today
Anakinra as a potential treatment for COVID-19.
- 1 Mar 2023
- Drugs of today (Barcelona, Spain : 1998)
New product intros
- 1 Mar 2023
- Drugs of Today
Secukinumab, ixekizumab, bimekizumab and brodalumab for psoriasis and psoriatic arthritis.
- 1 Mar 2023
- Drugs of Today
Tebentafusp: a novel drug for the treatment of metastatic uveal melanoma.
- 1 Mar 2023
- Drugs of Today
Cenegermin for the treatment of dry eye disease.
- 1 Mar 2023
- Drugs of Today
Sugemalimab, a novel PD-L1 inhibitor for treatment of advanced or metastatic non-small cell lung cancer.
- 1 Mar 2023
- Drugs of Today
Anakinra as a potential treatment for COVID-19.
- 1 Mar 2023
- Drugs of today (Barcelona, Spain : 1998)
FAQs on Drugs of Today
How long has Drugs of Today been actively publishing? 
What is the publishing frequency of Drugs of Today?
How many articles did Drugs of Today publish last year?
What is the eISSN & pISSN for Drugs of Today?
What is Citescore for Drugs of Today?
What is SNIP score for Drugs of Today?
Who is the publisher of Drugs of Today?
